The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines – Central Nervous System Cancers. V.1.2015. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed May 29, 2015.
2.
GilbertMR, DignamJJ, ArmstrongTS, A randomized trial of bevacizumab for newly diagnosed glioblastoma. New Engl J Med.2014;370(8):699–708.
3.
ChinotOL, WickW, MasonW, Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New Engl J Med.2014;370(8):709–722.
4.
NarayanaA, GruberD, KunnakkatS, A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg.2012;116(2):341–345.
5.
NeyDE, CarlsonJA, DamekDM, Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol.2015;122(1):133–143.
6.
OmuroA, BealK, GutinP, Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res.2014; 20(19):5023–5031.
7.
LaiA, TranA, NghiemphuPL, Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol.2011;29(2):142–148.
BaschE, PrestrudAA, HeskethP, Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.2011;29(31):4189–4198.
12.
RoilaF, HerrstedtJ, AaproM, Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol.2010;21(suppl 5) v232–v243.
TerreyJP, AaproMS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996;8:281–288.
15.
CarmichaelJ, KeizerHJ, CupissolD, MilliezJ, ScheidelP, SchindlerAE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998;9(5):381–385.
16.
de WitR, de BoerAC, vd LindenGH, StoterG, SparreboomA, VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001;19;85(8):1099–1101.
17.
SmithIE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993;119(6):350–354.
18.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2(3):177–183.
19.
DietrichJ, RaoK, PastorinoS, Corticosteroids in brain cancer patients: Benefits and pitfalls. Expert Rev Clin Pharmacol.2011;4(2):233–242.
20.
KostarasX, CusanoF, KlineG, Use of dexamethasone in patients with high-grade glioma: A clinical practice guideline. Curr Oncol2014;21(3):e493–503.
21.
RothP, WickW, WellerM.Steroids in neurooncology: Actions, indications, side effects. Curr Opin Neurol.2010;23(6):597–602.
22.
SmithTJ, KhatcheressianJ, LymanGH, 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol.2006;24(19):3187–3205.
ShahabI, PattersonWP. Renal and electrolyte abnormalities due to chemotherapy. In: PerryMC, ed. The Chemotherapy Sourcebook (4th ed). Philadelphia, PA: Lippincott Williams and Wilkins; 2008:223–233.
